Nuvation Bio backs off from head-to-head brain cancer trialnews2025-11-04T10:33:54+00:00November 4th, 2025|Endpoints News|
AbbVie gets early win in Oklahoma 340B fight, but faces setback in Coloradonews2025-11-03T20:18:49+00:00November 3rd, 2025|Endpoints News|
Lilly earmarks $3B for new European obesity pill factory news2025-11-03T17:58:52+00:00November 3rd, 2025|Endpoints News|
UK regulators look to speed up how rare disease therapies reach the marketnews2025-11-03T17:24:47+00:00November 3rd, 2025|Endpoints News|
Metsera calls Pfizer threats ‘nonsense’ as rift widens between companiesnews2025-11-03T16:46:46+00:00November 3rd, 2025|Endpoints News|
#ASH25: Lilly’s Jaypirca matches Imbruvica in Phase 3 early blood cancer trialnews2025-11-03T14:00:27+00:00November 3rd, 2025|Endpoints News|
#ASH25: Vertex, CRISPR say Casgevy shows promise in younger childrennews2025-11-03T14:00:17+00:00November 3rd, 2025|Endpoints News|
BioNTech ups sales guidance after Bristol Myers’ bispecific paymentnews2025-11-03T11:45:21+00:00November 3rd, 2025|Endpoints News|
Pfizer sues to stop Novo’s Metsera takeover attemptnews2025-10-31T20:41:12+00:00October 31st, 2025|Endpoints News|
Hawaii federal judge rules against FDA decision to maintain abortion pill restrictions news2025-10-31T19:27:00+00:00October 31st, 2025|Endpoints News|
